Y-mAbs Therapeutics, Inc. (YMAB)
NASDAQ: YMAB · Real-Time Price · USD
4.500
+0.070 (1.58%)
Apr 1, 2025, 4:00 PM EDT - Market closed

Y-mAbs Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2016
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2016
Net Income
-29.67-21.43-95.57-55.28-119.34
Upgrade
Depreciation & Amortization
0.540.740.840.780.4
Upgrade
Loss (Gain) From Sale of Assets
----62.01-
Upgrade
Stock-Based Compensation
14.5614.4525.619.3316.14
Upgrade
Provision & Write-off of Bad Debts
0.52----
Upgrade
Other Operating Activities
1.99-1.263.581.98.13
Upgrade
Change in Accounts Receivable
2.25-9.92-4.82-7.71-
Upgrade
Change in Inventory
-2.151.64-1.19-5.51-
Upgrade
Change in Accounts Payable
-1.39-6.86-0.924.180.85
Upgrade
Change in Other Net Operating Assets
-2.36-4.59-3.441.762.59
Upgrade
Operating Cash Flow
-15.71-27.23-75.92-102.56-91.23
Upgrade
Capital Expenditures
----0.67-0.18
Upgrade
Sale of Property, Plant & Equipment
---62.01-
Upgrade
Sale (Purchase) of Intangibles
----0.3-
Upgrade
Other Investing Activities
-----2.61
Upgrade
Investing Cash Flow
---61.04-2.79
Upgrade
Issuance of Common Stock
4.310.10.08108.312
Upgrade
Financing Cash Flow
4.310.10.08108.312
Upgrade
Foreign Exchange Rate Adjustments
-0.010.040.13-0.49
Upgrade
Net Cash Flow
-11.4-27.13-75.866.93-92.5
Upgrade
Free Cash Flow
-15.71-27.23-75.92-103.22-91.41
Upgrade
Free Cash Flow Margin
-17.92%-32.11%-116.32%-295.79%-440.51%
Upgrade
Free Cash Flow Per Share
-0.35-0.62-1.74-2.39-2.28
Upgrade
Cash Income Tax Paid
0.710.37---
Upgrade
Levered Free Cash Flow
4.44-14.03-28.3-58.6-57.01
Upgrade
Unlevered Free Cash Flow
4.44-14.03-28.3-57.44-57.01
Upgrade
Change in Net Working Capital
-5.0415.982.664.45-1.59
Upgrade
Updated Mar 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q